Epilepsy, Molecular Mechanisms of Pharmalogical Action, Protective Agents
Conditions
Keywords
Drug therapy, Positron Emission Tomography, Brain enzyme occupancy, Cholesterol 24S-hydroxylase, CH24H
Brief summary
The purpose of this study is to determine the brain cholesterol 24S-hydroxylase (CH24H) enzyme occupancy of TAK-935 after single oral dose in healthy participants using the positron emission tomography (PET) ligand \[18F\]MNI-792 and PET imaging and to determine the relationship of occupancy to TAK-935 exposure.
Detailed description
The drug being tested in this study is called TAK-935. TAK-935 is being tested to examine the degree and duration of brain CH24H enzyme occupancy/target engagement as a function of TAK-935 plasma concentration in order to guide dosing and schedule for future clinical trials with TAK-935. This study will utilize the PET ligand \[18F\]MNI-792 to evaluate the brain CH24H occupancy of TAK-935 after single dose oral administration in healthy adult participants. The study will evaluate up to 16 participants. The first 2 participants will take TAK-935 600 mg oral solution and undergo PET imaging using tracer \[18F\]MNI-792 up to 5 mcg (up to 370 MBq), injection, intravenously prior to each PET scan at Baseline, 45 minutes and 10 hours post-TAK-935 dose. TAK-935 dose and timing of post-dose scans for subsequent participants will be based on the data from the previous participants. This single-center trial will be conducted in the United States. The overall time to participate in this study is up to 55 days. Participants will make 4 visits to the clinic, including 2 confinement periods to the clinic for PET imaging. Participants will be contacted by phone on Day 28 for follow-up safety assessments.
Interventions
DRUGTAK-935
TAK-935 oral solution.
DRUG[18F]MNI-792 (tracer)
\[18F\]MNI-792 injection.
Sponsors
Takeda
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. In the opinion of the investigator, is capable of understanding and complying with protocol requirements. 2. Signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures including requesting that a participant fast for any laboratory evaluations. 3. Is a healthy male or female and aged 19 to 55 years, inclusive, at the time of informed consent and first study medication dose. 4. Weighs at least 45 kilogram (kg) and has a body mass index (BMI) from 18.0 to 30.0 kilogram per square meter (kg/m\^2), inclusive at Screening. 5. A female of non-bearing potential (example post-menopausal by history; or history of hysterectomy, bilateral salpingectomy, or oophorectomy).
Exclusion criteria
1. Have a known history or evidence of a clinically significant disorder (including neurologic and psychiatric), or disease that in the opinion of the study investigator would pose a risk to the participant safety or interfere with the study evaluation, procedures or completion. 2. Contraindication to magnetic resonance imaging (MRI) based on the standard MRI radiography screening questionnaire. 3. Had exposure to any radiation greater than (\>) 15 millisievert (mSv)/year (example, occupational or radiation therapy) within the previous year prior to Baseline imaging. 4. Has a known hypersensitivity to any component of the formulation of TAK-935 or related compounds, or to \[18F\]MNI-792 or to any of its components. 5. Clinically significant abnormal findings on brain MRI scan or findings on brain MRI that may interfere with the interpretation of the PET imaging. 6. Use of any over-the-counter, herbal, or prescription medications or supplements within 30 days prior to baseline imaging.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cholesterol 24S-Hydroxylase (CH24H) Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 45 Minutes Post-TAK-935 Dose | 45 minutes post-TAK-935 dose | CH24H brain enzyme occupancy was obtained by graphical analysis of global occupancy plot. Global occupancy plot was calculated as: total volume of distribution \[VT\] (Baseline) - VT (Day 1) = Occupancy (Day 1) \* (VT \[Baseline\] - non-displaceable volume of distribution \[VND\]), where VT (Baseline) and VT (Day 1) are the total distribution volumes obtained at Baseline and after TAK-935 administration, respectively and VND is the non-displaceable volume of distribution. The occupancy is determined as the slope of the linear regression of the plot, and the VND as the x-intercept. Data was reported only for TAK-935 600 mg because only first two participants were analyzed at 45 minutes post-TAK-935 dose. |
| CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 2 Hours Post-TAK-935 Dose | 2 hours post-TAK-935 dose | CH24H brain enzyme occupancy was obtained by graphical analysis of global occupancy plot. Global occupancy plot was calculated as: VT (Baseline) - VT (Day 1) = Occupancy (Day 1) \* (VT \[Baseline\] - VND), where VT (Baseline) and VT (Day 1) are the total distribution volumes obtained at Baseline and after TAK-935 administration, respectively and VND is the non-displaceable volume of distribution. The occupancy is determined as the slope of the linear regression of the plot, and the VND as the x-intercept. |
| CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 10 Hours Post-TAK-935 Dose | 10 hours post-TAK-935 dose | CH24H brain enzyme occupancy was obtained by graphical analysis of global occupancy plot. Global occupancy plot was calculated as: VT (Baseline) - VT (Day 1) = Occupancy (Day 1) \* (VT \[Baseline\] - VND), where VT (Baseline) and VT (Day 1) are the total distribution volumes obtained at Baseline and after TAK-935 administration, respectively and VND is the non-displaceable volume of distribution. The occupancy is determined as the slope of the linear regression of the plot, and the VND as the x-intercept. Data was reported only for TAK-935 600 mg because only first two participants were analyzed at 10 hour post-TAK-935 dose. |
| CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 24 Hours Post-TAK-935 Dose | 24 hours post-TAK-935 dose | CH24H brain enzyme occupancy was obtained by graphical analysis of global occupancy plot. Global occupancy plot was calculated as: VT (Baseline) - VT (Day 1) = Occupancy (Day 1) \* (VT \[Baseline\] - VND), where VT (Baseline) and VT (Day 1) are the total distribution volumes obtained at Baseline and after TAK-935 administration, respectively and VND is the non-displaceable volume of distribution. The occupancy is determined as the slope of the linear regression of the plot, and the VND as the x-intercept. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | At time 0 (just after tracer injection), 1 hour after tracer injection and 2 hours after tracer injection for each post-TAK-935 dosing PET scan period | — |
| Percent Change From Baseline in the AUEC24 for Plasma 24S Hydroxycholesterol (24HC) | Baseline (Day -1): 1 hour and at multiple timepoints (up to 12 hours) post check in and Day 1: pre-dose and at multiple timepoints (up to 24 hours) post-TAK-935 dose | Percent change was calculated as = \[(Postdose AUEC24(2) - Baseline AUEC24(2))/Baseline AUEC24(2)\]\*100 percent. |
Countries
United States
Contacts
STUDY_DIRECTORMedical Director
Takeda (Note: This product was divested to Mistrau Bio, Inc. in 2026)
Participant flow
Recruitment details
Participants took part in the study at 1 investigative site in the United States from 01 July 2015 to 04 January 2016.
Pre-assignment details
Healthy participants received up to 370 megabecquerel (MBq) (10 millicurie \[mCi\]) of \[18F\]MNI-792 with a mass of up to 5 microgram (mcg) at baseline and were enrolled to 1 of 5 treatment groups: TAK-935 50 milligram (mg), 100 mg, 200 mg, 300 mg, and 600 mg.
Participants by arm
| Arm | Count |
|---|---|
| TAK-935 50 mg TAK-935 50 mg, solution, orally, once on Day 1 and up to 370 MBq (10 mCi) of \[18F\]MNI-792 with a mass of up to 5 mcg, injection, intravenously, prior to PET imaging at 2 hours and 24 hours post-TAK-935 dose. | 2 |
| TAK-935 100 mg TAK-935 100 mg, solution, orally, once on Day 1 and up to 370 MBq (10mCi) of \[18F\]MNI-792 with a mass of up to 5 mcg, injection, intravenously, prior to PET imaging at Baseline, 2 hours and 24 hours post-TAK-935 dose. | 2 |
| TAK-935 200 mg TAK-935 200 mg, solution, orally, once on Day 1 and up to 370 MBq (10mCi) of \[18F\]MNI-792 with a mass of up to 5 mcg, injection, intravenously, prior to PET imaging at Baseline, 2 hours and 24 hours post-TAK-935 dose. | 2 |
| TAK-935 300 mg TAK-935 300 mg, solution, orally, once on Day 1 and up to 370 MBq (10mCi) of \[18F\]MNI-792 with a mass of up to 5 mcg, injection, intravenously, prior to PET imaging at Baseline, 2 hours and 24 hours post-TAK-935 dose. | 2 |
| TAK-935 600 mg TAK-935 600 mg, solution, orally, once on Day 1 and up to 370 MBq (10mCi) of \[18F\]MNI-792 with a mass of up to 5 mcg, injection, intravenously, prior to first PET imaging at Baseline, 45 minutes and 10 hours post-TAK-935 dose for the first 2 enrolled participants and at Baseline, 2 hours and 24 hours post-TAK-935 dose for the participant enrolled later. | 3 |
| Total | 11 |
Baseline characteristics
| Characteristic | TAK-935 50 mg | TAK-935 100 mg | TAK-935 200 mg | TAK-935 300 mg | TAK-935 600 mg | Total |
|---|---|---|---|---|---|---|
| Age, Continuous | 40.0 years STANDARD_DEVIATION 7.07 | 25.5 years STANDARD_DEVIATION 2.12 | 42.0 years STANDARD_DEVIATION 2.83 | 48.5 years STANDARD_DEVIATION 2.12 | 36.7 years STANDARD_DEVIATION 6.11 | 38.4 years STANDARD_DEVIATION 8.48 |
| Body Mass Index (BMI) | 29.22 kilogram per square meter (kg/m^2) STANDARD_DEVIATION 0.789 | 28.37 kilogram per square meter (kg/m^2) STANDARD_DEVIATION 2.157 | 25.46 kilogram per square meter (kg/m^2) STANDARD_DEVIATION 5.327 | 26.87 kilogram per square meter (kg/m^2) STANDARD_DEVIATION 1.593 | 24.95 kilogram per square meter (kg/m^2) STANDARD_DEVIATION 4.275 | 26.79 kilogram per square meter (kg/m^2) STANDARD_DEVIATION 3.212 |
| Ethnicity Hispanic or Latino | 1 participants | 2 participants | 0 participants | 0 participants | 1 participants | 4 participants |
| Ethnicity Not Hispanic or Latino | 1 participants | 0 participants | 2 participants | 2 participants | 2 participants | 7 participants |
| Height | 171.5 centimeter (cm) STANDARD_DEVIATION 4.95 | 181.5 centimeter (cm) STANDARD_DEVIATION 3.54 | 177.0 centimeter (cm) STANDARD_DEVIATION 4.24 | 180.0 centimeter (cm) STANDARD_DEVIATION 0 | 183.0 centimeter (cm) STANDARD_DEVIATION 16.09 | 179.0 centimeter (cm) STANDARD_DEVIATION 8.69 |
| Race Black or African American | 2 participants | 1 participants | 2 participants | 0 participants | 1 participants | 6 participants |
| Race White | 0 participants | 1 participants | 0 participants | 2 participants | 2 participants | 5 participants |
| Region of Enrollment United States | 2 participants | 2 participants | 2 participants | 2 participants | 3 participants | 11 participants |
| Sex/Gender, Customized Male | 2 participants | 2 participants | 2 participants | 2 participants | 3 participants | 11 participants |
| Weight | 86.05 kilogram (kg) STANDARD_DEVIATION 7.283 | 93.60 kilogram (kg) STANDARD_DEVIATION 10.748 | 79.40 kilogram (kg) STANDARD_DEVIATION 12.869 | 87.05 kilogram (kg) STANDARD_DEVIATION 5.162 | 84.83 kilogram (kg) STANDARD_DEVIATION 23.692 | 86.06 kilogram (kg) STANDARD_DEVIATION 13.009 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk |
|---|---|---|---|---|---|---|
| other Total, other adverse events | 1 / 11 | 1 / 2 | 1 / 2 | 1 / 2 | 1 / 2 | 1 / 3 |
| serious Total, serious adverse events | 0 / 11 | 0 / 2 | 0 / 2 | 0 / 2 | 0 / 2 | 0 / 3 |
Outcome results
Primary
CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 10 Hours Post-TAK-935 Dose
CH24H brain enzyme occupancy was obtained by graphical analysis of global occupancy plot. Global occupancy plot was calculated as: VT (Baseline) - VT (Day 1) = Occupancy (Day 1) \* (VT \[Baseline\] - VND), where VT (Baseline) and VT (Day 1) are the total distribution volumes obtained at Baseline and after TAK-935 administration, respectively and VND is the non-displaceable volume of distribution. The occupancy is determined as the slope of the linear regression of the plot, and the VND as the x-intercept. Data was reported only for TAK-935 600 mg because only first two participants were analyzed at 10 hour post-TAK-935 dose.
Time frame: 10 hours post-TAK-935 dose
Population: PET target occupancy set where 10 hour post-TAK-935-dose assessment were available. PET target occupancy set included all participants who received study drug (TAK-935) and had a technically adequate Baseline PET scan and at least 1 technically adequate post-TAK-935 dose PET scan.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| TAK-935 600 mg | CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 10 Hours Post-TAK-935 Dose | Participant 1 | 92 percentage of occupancy |
| TAK-935 600 mg | CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 10 Hours Post-TAK-935 Dose | Participant 2 | 87 percentage of occupancy |
| TAK-935 600 mg | CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 10 Hours Post-TAK-935 Dose | Participant 3 | NA percentage of occupancy |
Primary
CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 24 Hours Post-TAK-935 Dose
CH24H brain enzyme occupancy was obtained by graphical analysis of global occupancy plot. Global occupancy plot was calculated as: VT (Baseline) - VT (Day 1) = Occupancy (Day 1) \* (VT \[Baseline\] - VND), where VT (Baseline) and VT (Day 1) are the total distribution volumes obtained at Baseline and after TAK-935 administration, respectively and VND is the non-displaceable volume of distribution. The occupancy is determined as the slope of the linear regression of the plot, and the VND as the x-intercept.
Time frame: 24 hours post-TAK-935 dose
Population: PET target occupancy set where 24 hour post-TAK-935-dose assessment were available. PET target occupancy set included all participants who received study drug (TAK-935) and had a technically adequate Baseline PET scan and at least 1 technically adequate post-TAK-935 dose PET scan.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| TAK-935 600 mg | CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 24 Hours Post-TAK-935 Dose | Participant 1 | 22 percentage of occupancy |
| TAK-935 600 mg | CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 24 Hours Post-TAK-935 Dose | Participant 3 | NA percentage of occupancy |
| TAK-935 600 mg | CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 24 Hours Post-TAK-935 Dose | Participant 2 | 11 percentage of occupancy |
| TAK-935 100 mg | CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 24 Hours Post-TAK-935 Dose | Participant 2 | NA percentage of occupancy |
| TAK-935 100 mg | CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 24 Hours Post-TAK-935 Dose | Participant 1 | 13 percentage of occupancy |
| TAK-935 100 mg | CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 24 Hours Post-TAK-935 Dose | Participant 3 | NA percentage of occupancy |
| TAK-935 200 mg | CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 24 Hours Post-TAK-935 Dose | Participant 2 | 47 percentage of occupancy |
| TAK-935 200 mg | CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 24 Hours Post-TAK-935 Dose | Participant 1 | 79 percentage of occupancy |
| TAK-935 200 mg | CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 24 Hours Post-TAK-935 Dose | Participant 3 | NA percentage of occupancy |
| TAK-935 300 mg | CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 24 Hours Post-TAK-935 Dose | Participant 1 | 46 percentage of occupancy |
| TAK-935 300 mg | CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 24 Hours Post-TAK-935 Dose | Participant 3 | NA percentage of occupancy |
| TAK-935 300 mg | CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 24 Hours Post-TAK-935 Dose | Participant 2 | 27 percentage of occupancy |
| TAK-935 600 mg | CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 24 Hours Post-TAK-935 Dose | Participant 2 | NA percentage of occupancy |
| TAK-935 600 mg | CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 24 Hours Post-TAK-935 Dose | Participant 1 | NA percentage of occupancy |
| TAK-935 600 mg | CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 24 Hours Post-TAK-935 Dose | Participant 3 | 52 percentage of occupancy |
Primary
CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 2 Hours Post-TAK-935 Dose
CH24H brain enzyme occupancy was obtained by graphical analysis of global occupancy plot. Global occupancy plot was calculated as: VT (Baseline) - VT (Day 1) = Occupancy (Day 1) \* (VT \[Baseline\] - VND), where VT (Baseline) and VT (Day 1) are the total distribution volumes obtained at Baseline and after TAK-935 administration, respectively and VND is the non-displaceable volume of distribution. The occupancy is determined as the slope of the linear regression of the plot, and the VND as the x-intercept.
Time frame: 2 hours post-TAK-935 dose
Population: PET target occupancy set where 2 hour post-TAK-935-dose assessment were available. PET target occupancy set included all participants who received study drug (TAK-935) and had a technically adequate Baseline PET scan and at least 1 technically adequate post-TAK-935 dose PET scan.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| TAK-935 600 mg | CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 2 Hours Post-TAK-935 Dose | Participant 1 | 70 percentage of occupancy |
| TAK-935 600 mg | CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 2 Hours Post-TAK-935 Dose | Participant 3 | NA percentage of occupancy |
| TAK-935 600 mg | CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 2 Hours Post-TAK-935 Dose | Participant 2 | 64 percentage of occupancy |
| TAK-935 100 mg | CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 2 Hours Post-TAK-935 Dose | Participant 2 | 85 percentage of occupancy |
| TAK-935 100 mg | CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 2 Hours Post-TAK-935 Dose | Participant 1 | 79 percentage of occupancy |
| TAK-935 100 mg | CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 2 Hours Post-TAK-935 Dose | Participant 3 | NA percentage of occupancy |
| TAK-935 200 mg | CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 2 Hours Post-TAK-935 Dose | Participant 2 | 89 percentage of occupancy |
| TAK-935 200 mg | CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 2 Hours Post-TAK-935 Dose | Participant 1 | 96 percentage of occupancy |
| TAK-935 200 mg | CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 2 Hours Post-TAK-935 Dose | Participant 3 | NA percentage of occupancy |
| TAK-935 300 mg | CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 2 Hours Post-TAK-935 Dose | Participant 1 | 91 percentage of occupancy |
| TAK-935 300 mg | CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 2 Hours Post-TAK-935 Dose | Participant 3 | NA percentage of occupancy |
| TAK-935 300 mg | CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 2 Hours Post-TAK-935 Dose | Participant 2 | 89 percentage of occupancy |
| TAK-935 600 mg | CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 2 Hours Post-TAK-935 Dose | Participant 2 | NA percentage of occupancy |
| TAK-935 600 mg | CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 2 Hours Post-TAK-935 Dose | Participant 1 | NA percentage of occupancy |
| TAK-935 600 mg | CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 2 Hours Post-TAK-935 Dose | Participant 3 | 96 percentage of occupancy |
Primary
Cholesterol 24S-Hydroxylase (CH24H) Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 45 Minutes Post-TAK-935 Dose
CH24H brain enzyme occupancy was obtained by graphical analysis of global occupancy plot. Global occupancy plot was calculated as: total volume of distribution \[VT\] (Baseline) - VT (Day 1) = Occupancy (Day 1) \* (VT \[Baseline\] - non-displaceable volume of distribution \[VND\]), where VT (Baseline) and VT (Day 1) are the total distribution volumes obtained at Baseline and after TAK-935 administration, respectively and VND is the non-displaceable volume of distribution. The occupancy is determined as the slope of the linear regression of the plot, and the VND as the x-intercept. Data was reported only for TAK-935 600 mg because only first two participants were analyzed at 45 minutes post-TAK-935 dose.
Time frame: 45 minutes post-TAK-935 dose
Population: PET target occupancy set where 45 minutes post-TAK-935-dose assessment were available. PET target occupancy set included all participants who received study drug (TAK-935) and had a technically adequate Baseline PET scan and at least 1 technically adequate post-TAK-935 dose PET scan.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| TAK-935 600 mg | Cholesterol 24S-Hydroxylase (CH24H) Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 45 Minutes Post-TAK-935 Dose | Participant 1 | NA percentage of occupancy |
| TAK-935 600 mg | Cholesterol 24S-Hydroxylase (CH24H) Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 45 Minutes Post-TAK-935 Dose | Participant 2 | 98 percentage of occupancy |
| TAK-935 600 mg | Cholesterol 24S-Hydroxylase (CH24H) Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 45 Minutes Post-TAK-935 Dose | Participant 3 | NA percentage of occupancy |
Secondary
Percent Change From Baseline in the AUEC24 for Plasma 24S Hydroxycholesterol (24HC)
Percent change was calculated as = \[(Postdose AUEC24(2) - Baseline AUEC24(2))/Baseline AUEC24(2)\]\*100 percent.
Time frame: Baseline (Day -1): 1 hour and at multiple timepoints (up to 12 hours) post check in and Day 1: pre-dose and at multiple timepoints (up to 24 hours) post-TAK-935 dose
Population: PK set included all participants who received TAK-935 and had at least 1 measurable plasma concentration for either TAK-935 or its M-1 metabolite. Data was reported for Participant 1 and 2 of each of TAK-935 50, 100, 200, and 300 mg arms and Participant 1, 2, and 3 of TAK-935 600 mg arm.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| TAK-935 600 mg | Percent Change From Baseline in the AUEC24 for Plasma 24S Hydroxycholesterol (24HC) | Participant 1 | -6.79 percent change |
| TAK-935 600 mg | Percent Change From Baseline in the AUEC24 for Plasma 24S Hydroxycholesterol (24HC) | Participant 3 | NA percent change |
| TAK-935 600 mg | Percent Change From Baseline in the AUEC24 for Plasma 24S Hydroxycholesterol (24HC) | Participant 2 | -13.38 percent change |
| TAK-935 100 mg | Percent Change From Baseline in the AUEC24 for Plasma 24S Hydroxycholesterol (24HC) | Participant 2 | -15.04 percent change |
| TAK-935 100 mg | Percent Change From Baseline in the AUEC24 for Plasma 24S Hydroxycholesterol (24HC) | Participant 1 | -14.82 percent change |
| TAK-935 100 mg | Percent Change From Baseline in the AUEC24 for Plasma 24S Hydroxycholesterol (24HC) | Participant 3 | NA percent change |
| TAK-935 200 mg | Percent Change From Baseline in the AUEC24 for Plasma 24S Hydroxycholesterol (24HC) | Participant 2 | -9.30 percent change |
| TAK-935 200 mg | Percent Change From Baseline in the AUEC24 for Plasma 24S Hydroxycholesterol (24HC) | Participant 1 | -10.50 percent change |
| TAK-935 200 mg | Percent Change From Baseline in the AUEC24 for Plasma 24S Hydroxycholesterol (24HC) | Participant 3 | NA percent change |
| TAK-935 300 mg | Percent Change From Baseline in the AUEC24 for Plasma 24S Hydroxycholesterol (24HC) | Participant 1 | -12.41 percent change |
| TAK-935 300 mg | Percent Change From Baseline in the AUEC24 for Plasma 24S Hydroxycholesterol (24HC) | Participant 3 | NA percent change |
| TAK-935 300 mg | Percent Change From Baseline in the AUEC24 for Plasma 24S Hydroxycholesterol (24HC) | Participant 2 | -18.55 percent change |
| TAK-935 600 mg | Percent Change From Baseline in the AUEC24 for Plasma 24S Hydroxycholesterol (24HC) | Participant 2 | -12.79 percent change |
| TAK-935 600 mg | Percent Change From Baseline in the AUEC24 for Plasma 24S Hydroxycholesterol (24HC) | Participant 1 | -7.23 percent change |
| TAK-935 600 mg | Percent Change From Baseline in the AUEC24 for Plasma 24S Hydroxycholesterol (24HC) | Participant 3 | -6.81 percent change |
Secondary
Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods
Time frame: At time 0 (just after tracer injection), 1 hour after tracer injection and 2 hours after tracer injection for each post-TAK-935 dosing PET scan period
Population: Pharmacokinetic (PK) set included all participants who received TAK-935 and had at least 1 measurable plasma concentration for either TAK-935 or its M-1 metabolite. Data was reported for Participant 1 and 2 of each of TAK-935 50, 100, 200, and 300 mg arms and Participant 1, 2, and 3 of TAK-935 600 mg arm.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| TAK-935 600 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 1:PET Scan 1: 2 hours post-tracer dose | 2.98 nanogram per milliliter (ng/mL) |
| TAK-935 600 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 2: PET Scan 1: 1 hour post-tracer dose | 2.97 nanogram per milliliter (ng/mL) |
| TAK-935 600 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 1: PET Scan 1: 1 hour post-tracer dose | 3.79 nanogram per milliliter (ng/mL) |
| TAK-935 600 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 1: PET Scan 1: pre-tracer dose | 9.16 nanogram per milliliter (ng/mL) |
| TAK-935 600 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 1:PET Scan 2: 1 hour post-tracer dose | NA nanogram per milliliter (ng/mL) |
| TAK-935 600 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 3: PET Scan 1: pre-tracer dose | NA nanogram per milliliter (ng/mL) |
| TAK-935 600 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 2: PET Scan 1: pre-tracer dose | 6.92 nanogram per milliliter (ng/mL) |
| TAK-935 600 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 1:PET Scan 2:2 hours post-tracer dose | NA nanogram per milliliter (ng/mL) |
| TAK-935 600 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 3: PET Scan 2: 1 hour post-tracer dose | NA nanogram per milliliter (ng/mL) |
| TAK-935 600 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 3:PET Scan 1: 2 hours post-tracer dose | NA nanogram per milliliter (ng/mL) |
| TAK-935 600 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 2: PET Scan 2: pre-tracer dose | NA nanogram per milliliter (ng/mL) |
| TAK-935 600 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 2:PET Scan 2:2 hours post-tracer dose | NA nanogram per milliliter (ng/mL) |
| TAK-935 600 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 3:PET Scan 2: 2 hours post-tracer dose | NA nanogram per milliliter (ng/mL) |
| TAK-935 600 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 3: PET Scan 1: 1 hour post-tracer dose | NA nanogram per milliliter (ng/mL) |
| TAK-935 600 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 2:PET Scan 1: 2 hours post-tracer dose | 1.95 nanogram per milliliter (ng/mL) |
| TAK-935 600 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 2:PET Scan 2: 1 hour post-tracer dose | NA nanogram per milliliter (ng/mL) |
| TAK-935 600 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 3: PET Scan 2: pre-tracer dose | NA nanogram per milliliter (ng/mL) |
| TAK-935 600 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 1: PET Scan 2: pre-tracer dose | NA nanogram per milliliter (ng/mL) |
| TAK-935 100 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 2: PET Scan 1: pre-tracer dose | 23.9 nanogram per milliliter (ng/mL) |
| TAK-935 100 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 2:PET Scan 2:2 hours post-tracer dose | NA nanogram per milliliter (ng/mL) |
| TAK-935 100 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 3: PET Scan 1: pre-tracer dose | NA nanogram per milliliter (ng/mL) |
| TAK-935 100 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 1:PET Scan 1: 2 hours post-tracer dose | 2.45 nanogram per milliliter (ng/mL) |
| TAK-935 100 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 3: PET Scan 1: 1 hour post-tracer dose | NA nanogram per milliliter (ng/mL) |
| TAK-935 100 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 1: PET Scan 1: pre-tracer dose | 11.3 nanogram per milliliter (ng/mL) |
| TAK-935 100 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 1: PET Scan 2: pre-tracer dose | NA nanogram per milliliter (ng/mL) |
| TAK-935 100 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 3: PET Scan 2: 1 hour post-tracer dose | NA nanogram per milliliter (ng/mL) |
| TAK-935 100 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 1:PET Scan 2: 1 hour post-tracer dose | NA nanogram per milliliter (ng/mL) |
| TAK-935 100 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 1:PET Scan 2:2 hours post-tracer dose | NA nanogram per milliliter (ng/mL) |
| TAK-935 100 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 3:PET Scan 2: 2 hours post-tracer dose | NA nanogram per milliliter (ng/mL) |
| TAK-935 100 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 3: PET Scan 2: pre-tracer dose | NA nanogram per milliliter (ng/mL) |
| TAK-935 100 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 2: PET Scan 1: 1 hour post-tracer dose | 12.3 nanogram per milliliter (ng/mL) |
| TAK-935 100 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 1: PET Scan 1: 1 hour post-tracer dose | 5.02 nanogram per milliliter (ng/mL) |
| TAK-935 100 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 2:PET Scan 1: 2 hours post-tracer dose | 6.46 nanogram per milliliter (ng/mL) |
| TAK-935 100 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 2: PET Scan 2: pre-tracer dose | 1.83 nanogram per milliliter (ng/mL) |
| TAK-935 100 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 3:PET Scan 1: 2 hours post-tracer dose | NA nanogram per milliliter (ng/mL) |
| TAK-935 100 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 2:PET Scan 2: 1 hour post-tracer dose | 1.28 nanogram per milliliter (ng/mL) |
| TAK-935 200 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 3: PET Scan 1: pre-tracer dose | NA nanogram per milliliter (ng/mL) |
| TAK-935 200 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 1: PET Scan 2: pre-tracer dose | 14.2 nanogram per milliliter (ng/mL) |
| TAK-935 200 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 2:PET Scan 2:2 hours post-tracer dose | NA nanogram per milliliter (ng/mL) |
| TAK-935 200 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 2: PET Scan 1: 1 hour post-tracer dose | 16.8 nanogram per milliliter (ng/mL) |
| TAK-935 200 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 2: PET Scan 2: pre-tracer dose | NA nanogram per milliliter (ng/mL) |
| TAK-935 200 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 3: PET Scan 2: 1 hour post-tracer dose | NA nanogram per milliliter (ng/mL) |
| TAK-935 200 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 1:PET Scan 1: 2 hours post-tracer dose | 30.3 nanogram per milliliter (ng/mL) |
| TAK-935 200 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 3: PET Scan 1: 1 hour post-tracer dose | NA nanogram per milliliter (ng/mL) |
| TAK-935 200 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 2:PET Scan 1: 2 hours post-tracer dose | 7.52 nanogram per milliliter (ng/mL) |
| TAK-935 200 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 3:PET Scan 2: 2 hours post-tracer dose | NA nanogram per milliliter (ng/mL) |
| TAK-935 200 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 1: PET Scan 1: 1 hour post-tracer dose | 72.7 nanogram per milliliter (ng/mL) |
| TAK-935 200 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 1:PET Scan 2:2 hours post-tracer dose | 8.08 nanogram per milliliter (ng/mL) |
| TAK-935 200 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 3:PET Scan 1: 2 hours post-tracer dose | NA nanogram per milliliter (ng/mL) |
| TAK-935 200 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 3: PET Scan 2: pre-tracer dose | NA nanogram per milliliter (ng/mL) |
| TAK-935 200 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 1:PET Scan 2: 1 hour post-tracer dose | 9.16 nanogram per milliliter (ng/mL) |
| TAK-935 200 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 2:PET Scan 2: 1 hour post-tracer dose | NA nanogram per milliliter (ng/mL) |
| TAK-935 200 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 2: PET Scan 1: pre-tracer dose | 34.8 nanogram per milliliter (ng/mL) |
| TAK-935 200 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 1: PET Scan 1: pre-tracer dose | 158 nanogram per milliliter (ng/mL) |
| TAK-935 300 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 3: PET Scan 2: pre-tracer dose | NA nanogram per milliliter (ng/mL) |
| TAK-935 300 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 1: PET Scan 1: pre-tracer dose | 56.2 nanogram per milliliter (ng/mL) |
| TAK-935 300 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 1: PET Scan 1: 1 hour post-tracer dose | 19.4 nanogram per milliliter (ng/mL) |
| TAK-935 300 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 1:PET Scan 1: 2 hours post-tracer dose | 12.9 nanogram per milliliter (ng/mL) |
| TAK-935 300 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 1: PET Scan 2: pre-tracer dose | NA nanogram per milliliter (ng/mL) |
| TAK-935 300 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 1:PET Scan 2: 1 hour post-tracer dose | NA nanogram per milliliter (ng/mL) |
| TAK-935 300 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 1:PET Scan 2:2 hours post-tracer dose | NA nanogram per milliliter (ng/mL) |
| TAK-935 300 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 2: PET Scan 1: pre-tracer dose | 50.9 nanogram per milliliter (ng/mL) |
| TAK-935 300 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 2: PET Scan 1: 1 hour post-tracer dose | 15.7 nanogram per milliliter (ng/mL) |
| TAK-935 300 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 2:PET Scan 1: 2 hours post-tracer dose | 14.6 nanogram per milliliter (ng/mL) |
| TAK-935 300 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 2: PET Scan 2: pre-tracer dose | NA nanogram per milliliter (ng/mL) |
| TAK-935 300 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 2:PET Scan 2: 1 hour post-tracer dose | NA nanogram per milliliter (ng/mL) |
| TAK-935 300 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 2:PET Scan 2:2 hours post-tracer dose | NA nanogram per milliliter (ng/mL) |
| TAK-935 300 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 3: PET Scan 1: pre-tracer dose | NA nanogram per milliliter (ng/mL) |
| TAK-935 300 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 3: PET Scan 1: 1 hour post-tracer dose | NA nanogram per milliliter (ng/mL) |
| TAK-935 300 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 3:PET Scan 1: 2 hours post-tracer dose | NA nanogram per milliliter (ng/mL) |
| TAK-935 300 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 3: PET Scan 2: 1 hour post-tracer dose | NA nanogram per milliliter (ng/mL) |
| TAK-935 300 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 3:PET Scan 2: 2 hours post-tracer dose | NA nanogram per milliliter (ng/mL) |
| TAK-935 600 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 2: PET Scan 2: pre-tracer dose | 7.99 nanogram per milliliter (ng/mL) |
| TAK-935 600 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 2:PET Scan 1: 2 hours post-tracer dose | 90.8 nanogram per milliliter (ng/mL) |
| TAK-935 600 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 3:PET Scan 1: 2 hours post-tracer dose | 155 nanogram per milliliter (ng/mL) |
| TAK-935 600 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 2: PET Scan 1: 1 hour post-tracer dose | 257 nanogram per milliliter (ng/mL) |
| TAK-935 600 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 2: PET Scan 1: pre-tracer dose | 569 nanogram per milliliter (ng/mL) |
| TAK-935 600 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 1:PET Scan 2:2 hours post-tracer dose | 14.4 nanogram per milliliter (ng/mL) |
| TAK-935 600 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 3: PET Scan 1: 1 hour post-tracer dose | 236 nanogram per milliliter (ng/mL) |
| TAK-935 600 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 3: PET Scan 2: pre-tracer dose | 3.04 nanogram per milliliter (ng/mL) |
| TAK-935 600 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 1:PET Scan 2: 1 hour post-tracer dose | 16 nanogram per milliliter (ng/mL) |
| TAK-935 600 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 1: PET Scan 2: pre-tracer dose | 22.3 nanogram per milliliter (ng/mL) |
| TAK-935 600 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 1:PET Scan 1: 2 hours post-tracer dose | 379 nanogram per milliliter (ng/mL) |
| TAK-935 600 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 3:PET Scan 2: 2 hours post-tracer dose | 2.24 nanogram per milliliter (ng/mL) |
| TAK-935 600 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 3: PET Scan 2: 1 hour post-tracer dose | 2.58 nanogram per milliliter (ng/mL) |
| TAK-935 600 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 1: PET Scan 1: 1 hour post-tracer dose | 200 nanogram per milliliter (ng/mL) |
| TAK-935 600 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 3: PET Scan 1: pre-tracer dose | 589 nanogram per milliliter (ng/mL) |
| TAK-935 600 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 2:PET Scan 2:2 hours post-tracer dose | 5.12 nanogram per milliliter (ng/mL) |
| TAK-935 600 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 1: PET Scan 1: pre-tracer dose | 6.83 nanogram per milliliter (ng/mL) |
| TAK-935 600 mg | Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods | Participant 2:PET Scan 2: 1 hour post-tracer dose | 6.27 nanogram per milliliter (ng/mL) |